The Only Non-invasive Test to Identify All Harmful Stages of MASLD.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease affecting 25% of the general population worldwide and is the leading cause of cirrhosis and liver transplantation in women. In the United States, MASLD affects an estimated 30%-40% of adults.
Clinical Need
There is a critical need for non-invasive tools that can detect MASLD in its early stages, before significant fibrosis develops and costly or invasive interventions are required.
Patients with risk factors such as obesity, diabetes, metabolic syndrome or dyslipidemia are at increased risk for MASLD.
CIMA Sciences, LLC is a biotechnology company focused in bringing to the scientific community and US population the best non-invasive diagnostic technology for high prevalence disease.
Founded in 2022 and based in San Antonio, Texas, CIMA Sciences is dedicated to advancing non-invasive diagnostic solutions for widespread medical conditions. With a focus on liver and cardiovascular health, our mission is to equip healthcare providers and researchers with innovative tools that enable earlier detection, improved patient outcomes, and more efficient clinical decision-making.
Advancing Non-Invasive Diagnostics.
Contact Us
300E Sonterra Blvd., Suite 1110
San Antonio, Texas 78258
Order OWLiver® Test
OWLiver® is a non-invasive blood test to assess MASLD. It analyzes a panel of biomarkers through metabolomics methodology.